Stopping Ruxolitinib Cream: What the Vitiligo Trial Measured

Once pigment returns, the next appointment may concern keeping that improvement rather than achieving it. A withdrawal study can inform that discussion only if you know who qualified and what the researchers counted as maintaining a response.

Who entered the withdrawal comparison?

The TRuE-V extension randomized 116 patients with at least 90% improvement in their facial Vitiligo Area Scoring Index at week 52. They continued 1.5% ruxolitinib twice daily or switched to vehicle cream for another year.¹

What did maintaining improvement mean?

The threshold was at least 75% facial-score improvement from the original baseline, not unchanged pigment. 22 of 56 evaluable withdrawal patients (39%) and 38 of 55 continuation patients (69%) maintained that response for one year.¹

26 of 116 discontinued treatment, more in the withdrawal arm. Missing follow-up must not be counted as relapse. These observed proportions differ from the paper’s time-to-event estimates.¹

Could lost improvement return?

Of 16 withdrawal patients who relapsed, 12 regained the 75% threshold after open-label retreatment. Incyte funded and helped conduct the study. Selected responders limit applicability.¹

A facial score is also different from a judgment about every patch on the body or how satisfied you feel with the change. Bring your own treatment goal back into the discussion: which area matters to you, whether the difference feels meaningful, and what applying the cream involves each day.

How does this fit the current US label?

The June 2026 OPZELURA label covers nonsegmental vitiligo from age 12, with twice-daily treatment of affected areas totaling up to 10% of body surface area. It says a satisfactory response may require more than 24 weeks, with reassessment if repigmentation is not meaningful by then. The withdrawal study does not replace that review.²

The label carries boxed warnings about serious infection, mortality, malignancy, major cardiovascular events and thrombosis. Some comparisons underlying these warnings concern oral JAK inhibitors in higher-risk rheumatoid-arthritis patients, rather than an identical risk estimate for vitiligo cream users. The cream still requires individual benefit/risk assessment, infection precautions and periodic skin examinations.²

Ask how the dermatologist will weigh continued benefit against your health history, medicine list and any adverse effects. A pigment-response percentage cannot answer those questions by itself.

Make the follow-up photograph useful

Bring dated photographs and the dates of any prescribed treatment changes. Keep lighting, camera distance and angle consistent so a darker photograph does not masquerade as a pigment change. Avoid using a phone filter to compare progress.

“Your First Thirty Days” in Skin, Head to Toe uses photographs in the same light, hour and distance and a Skin Log of products and reactions. Its general skin-care calendar does not determine how long to use a vitiligo prescription; the clinician’s plan takes priority.

Our vitiligo sunscreen and camouflage guide covers those separate choices. At the review, ask what change should trigger contact, when the next assessment will happen and how any prescribed withdrawal would be monitored.